Studies on the pathogenesis of human motor neurone disease have suffered from the absence of models of motor neurone degeneration in adult animals. Normally in adult rodents, transection of motor neurone axons results in only a modest degree of neuronal death.We reasoned that axotomy-induced motor neurone death might be enhanced by modulating glutamatergic transmission. By axotomizing the facial nerve in adult rats and then administering MK-801 for the first week of a 4-week or 8-week post-lesion survival period, we induced a 67% motor neurone loss by 8 weeks as compared with a 19% loss in controls. A possible explanation for the increased motor neurone loss after MK-801 treatment is that transient blockade of NMDA receptors may upregulate synthesis of NMDA receptor components. In order to test this idea, we employed quantitative in situ hybridization to determine the response of NMDAR1 mRNA to axotomy and axotomy + MK-801 treatment. Quantification of the percentage of area occupied by NMDAR1 silver grains per motor neurone somata indicated that axotomy alone did not provoke a change in NMDAR1 mRNA. However, axotomy and MK-801 combined treatment resulted in a highly significant upregulation of NMDAR1 mRNA when compared with controls or animals treated solely with axotomy.
Introduction
A variety of lines of evidence implicate glutamate in the pathogenesis of motor neurone death in amyotrophic lateral sclerosis (ALS). Thus, high-affinity glutamate transport is reduced in synaptosomes from spinal cord and motor cortex of patients with ALS compared with controls (Rothstein et al. 1992) . In animal studies, chronic pharmacological blockade of glutamate uptake in spinal cord slice preparations elevates glutamate concentrations which results in the degeneration of motor neurones (Rothstein et al. 1993) . Finally some studies have suggested that defective glutamate metabolism occurs in ALS patients (Plaitakis & Caroscio 1987 , Plaitakis et al. 1988 , Hugon et al. 1989 . Based on the results of these and other studies, drugs that modulate glutamatergic influences have been proposed for possible treatment in motor neurone disease. One such drug, Riluzole (2-amino-6-(trifluoromethoxy) bezothiazole, RP 54274) has already been tested and may slow the progression of disease, in a subset of ALS patients (Bensimon et al. 1994) . However, in spite of the attractiveness of the glutamate
